Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal bevacizumab for exudative macular diseases
2006-002351-33Phase 2Active
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
- Start
- Dec 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in macular edema, neovascular retinopathy (NVR), Subretinal neovascularization and 2 more, sponsored by Azienda Ospedaliera Universitaria Integrata Verona. Primary endpoint: Visual acuity letter change categories. Started Dec 2006; status: active.
02
Drugs
bevacizumab
03
Conditions
macular edemaneovascular retinopathy (NVR)Subretinal neovascularizationneovascular glaucoma (NVG)Exudative Maculopathy
Beyond the preview
Go deeper on 2006-002351-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002351-33.